Guided Therapeutics (GTHP) Net Margin (2010 - 2025)
Guided Therapeutics recorded quarterly Net Margin of 202.71% in Q4 2025, up 84.51% quarter-over-quarter from 1308.33% in Q3 2025, and up 6979729.0% year-over-year from N/an in Q4 2024.
Guided Therapeutics' Net Margin history runs 16 years deep, the most recent figure standing at 202.71% for Q4 2025.
- In Q4 2025, Net Margin rose 6979729.0% year-over-year to 202.71%; the TTM figure through Dec 2025 stood at 430.25% (up 3658404.0% YoY), while the FY2025 annual figure was 430.25%, up 3658404.0% from the prior year.
- Net Margin came in at 202.71% for Q4 2025 at Guided Therapeutics, up from 1308.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 202.71% in Q4 2025 to a low of 70000.0% in Q4 2024.
- A 5-year average of 16039.17% and a median of 4025.0% in 2023 frame the typical range for Net Margin.
- Across the five-year window, Net Margin tumbled 6853438 bps in 2024 and jumped 6979729 bps in 2025, its largest moves.
- Guided Therapeutics' Net Margin stood at 848.33% in 2021, then tumbled by 4041 bps to 35133.33% in 2022, then soared by 96 bps to 1465.62% in 2023, then plunged by 4676 bps to 70000.0% in 2024, then soared by 100 bps to 202.71% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 202.71%, 1308.33%, and 731.62% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 12.75% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.00% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 16.74% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 8.01% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Guided Therapeutics | - | - | 458,000.00 | -202.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -202.71% |
| Sep 30, 2025 | -1,308.33% |
| Jun 30, 2025 | -731.62% |
| Dec 31, 2024 | -70,000.00% |
| Mar 31, 2024 | -7,350.00% |
| Dec 31, 2023 | -1,465.63% |
| Jun 30, 2023 | -3,645.45% |
| Mar 31, 2023 | -4,404.55% |
| Sep 30, 2022 | -35,133.33% |
| Jun 30, 2022 | -20,140.00% |
| Mar 31, 2022 | -21,100.00% |
| Dec 31, 2021 | -848.33% |
| Sep 30, 2021 | -268.42% |
| Jun 30, 2021 | -57,950.00% |
| Dec 31, 2020 | 8,476.00% |
| Sep 30, 2020 | 1,985.71% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -265,400.00% |
| Mar 31, 2019 | -1,244.44% |
| Dec 31, 2018 | -6,547.62% |
| Sep 30, 2018 | -37,850.00% |
| Jun 30, 2018 | 42,225.00% |
| Mar 31, 2018 | 25,675.00% |
| Dec 31, 2017 | -6,741.12% |
| Sep 30, 2017 | -7,324.24% |
| Jun 30, 2017 | -1,306.90% |
| Mar 31, 2017 | -980.95% |
| Dec 31, 2016 | 430.86% |
| Sep 30, 2016 | -410.53% |
| Dec 31, 2015 | -27,644.44% |
| Sep 30, 2015 | -34,200.00% |
| Jun 30, 2015 | -30,010.00% |
| Mar 31, 2015 | -8,506.67% |
| Dec 31, 2014 | -24,784.62% |
| Sep 30, 2014 | -13,686.36% |
| Jun 30, 2014 | -19,936.36% |
| Mar 31, 2014 | -8,473.68% |
| Dec 31, 2013 | -1,218.79% |
| Sep 30, 2013 | -1,672.09% |
| Jun 30, 2013 | -1,315.77% |
| Mar 31, 2013 | -1,086.83% |
| Dec 31, 2012 | -117.29% |
| Sep 30, 2012 | -142.28% |
| Jun 30, 2012 | -127.54% |
| Mar 31, 2012 | 141.09% |
| Dec 31, 2011 | 308.15% |
| Sep 30, 2011 | 260.63% |
| Jun 30, 2011 | -54.33% |
| Mar 31, 2011 | 94.65% |
| Jun 30, 2010 | -69.44% |